LeMaitre Vascular, Inc. (LMAT), a specialty medical device company focused on peripheral vascular disease treatment, has captured investor attention as it trades near the upper end of its 52-week range. The stock closed at $103.57 on July 29, 2026, roughly 16% below the $120 price target that several Wall Street analysts have assigned. With a 52-week high of $118.01, the $120 mark represents more than a round number — it would confirm a breakout to new all-time highs and validate the bullish thesis that has driven the stock's multi-year uptrend.
Headquartered in Burlington, Massachusetts, LeMaitre Vascular develops, manufactures, and markets disposable and implantable vascular devices used primarily by vascular surgeons. Founded in 1983, the company has built a portfolio spanning over 16 product lines — including valvulotomes, carotid shunts, biologic patches, embolectomy catheters, and vascular grafts. With a market capitalization of approximately $2.37 billion, LMAT generates roughly 60% of its revenue in the Americas, with the remainder from Europe, the Middle East, Africa, and Asia-Pacific markets. The company's niche focus on open vascular surgery has allowed it to maintain pricing power and earn consistently high gross margins.
Several fundamental strengths support the case for LMAT reaching $120. The company delivered record revenue exceeding $228 million in fiscal 2025, with organic growth running in the low double digits. Gross margins have expanded to roughly 70%, driven by higher average selling prices and manufacturing efficiencies. The balance sheet remains debt-free, and free cash flow exceeded $53 million in the most recent trailing period, providing ample resources for internal investment, dividend payments, and potential acquisitions.
International expansion represents a significant growth runway. The company sells directly in 25 countries and through distributors in more than 70 others, and management has consistently highlighted new regulatory approvals and salesforce additions as levers for accelerating overseas revenue. Additionally, LeMaitre has filed for early cannulation labeling with the FDA for certain products — a potential catalyst that could expand its addressable market in the dialysis access space.
Analysts at Lake Street have set the highest Street target at $135, while Citizens JMP raised its target to $127 in May 2026, citing confidence in the company's earnings trajectory. Barrington Research and Stifel Nicolaus both reiterated $120 targets with Buy-equivalent ratings. The consensus among nine analysts tracked by S&P Global sits at approximately $118.75, with a "Buy" rating.
From a technical perspective, the $118.01 area represents the single most important resistance level — it marks the 52-week high and, based on available data, the all-time high for the stock. A decisive close above $118 would open the door toward $120 and potentially beyond. On the downside, the stock has established support near the $97–$100 zone, which aligns with recent consolidation levels and the 50-day moving average. The 200-day moving average, situated near $95, provides a deeper support floor.
LMAT's low beta of approximately 0.52 suggests the stock is less volatile than the broader market, which can be both a strength and a limitation — it may take longer to reach aggressive price targets, but downside risk during market turbulence is comparatively muted.
Valuation remains the most frequently cited concern. At roughly 38 times trailing earnings, LMAT trades at a premium compared to many peers in the medical instruments and supplies industry. While the forward P/E ratio of approximately 31 suggests earnings growth is expected, any earnings miss or downward guidance revision could trigger multiple compression that pushes $120 further out of reach.
Insider selling activity has also raised eyebrows. Over recent quarters, multiple executives, including senior operational leadership, have reduced positions. While insider selling can occur for personal financial planning reasons unrelated to company outlook, the volume of sales warrants attention.
Wells Fargo maintained an Equal-Weight rating with a $104 target — notably below the $120 threshold — reflecting a view that much of the good news may already be priced in. Cantor Fitzgerald likewise holds a Neutral stance. Additionally, the discontinuation of Aziyo distribution has created headwinds in the company's distribution sales channel, a drag that could persist in the near term.
The analyst community tilts bullish but not unanimously so. Of nine analysts covering the stock, five rate it Buy or equivalent, while four maintain Hold ratings — and none recommend selling. Price targets range from a low of $95 (Cantor Fitzgerald) to a high of $135 (Lake Street), with the $120 level emerging as the most frequently cited discrete target. This clustering around $120 gives the level added significance: it is not an arbitrary round number but a threshold that multiple research teams have independently identified as a fair-value estimate based on earnings projections and industry multiples.
For traders seeking to navigate price movements in stocks like LeMaitre Vascular, AI Daily Buy/Sell Signals from Tickeron offer a data-driven approach. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-powered analysis. These signals help traders identify emerging opportunities, manage existing positions more effectively, and stay ahead of changing market trends without manually scanning hundreds of charts. Whether the goal is discovering new setups or confirming existing convictions, incorporating AI-driven signals can add an additional layer of discipline to the decision-making process.
A move to $120 for LeMaitre Vascular appears realistic but is not guaranteed. The stock requires a gain of approximately 16% from current levels, which is within reach given the company's track record of double-digit revenue growth, expanding margins, and a debt-free balance sheet. The strongest arguments in favor include broad analyst support, multiple growth catalysts — international expansion, new product approvals, and potential M&A — and a demonstrated ability to increase prices in niche markets with limited competition.
The primary risks center on valuation, which already embeds significant growth expectations, and the technical hurdle presented by the $118 resistance zone. Any earnings disappointment, broader sector rotation away from healthcare, or unexpected competitive pressures could delay or derail the advance. Investors monitoring LMAT should pay close attention to upcoming quarterly results, particularly the Q2 2026 earnings report expected in early August, as well as any updates on international sales momentum and FDA-related product developments.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, LMAT has been loosely correlated with ITGR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LMAT jumps, then ITGR could also see price increases.
| Ticker / NAME | Correlation To LMAT | 1D Price Change % | ||
|---|---|---|---|---|
| LMAT | 100% | -0.85% | ||
| ITGR - LMAT | 48% Loosely correlated | +20.18% | ||
| SYK - LMAT | 46% Loosely correlated | -6.42% | ||
| UFPT - LMAT | 44% Loosely correlated | -0.10% | ||
| AORT - LMAT | 40% Loosely correlated | -3.04% | ||
| RDNT - LMAT | 39% Loosely correlated | +1.74% | ||
More | ||||
| Ticker / NAME | Correlation To LMAT | 1D Price Change % |
|---|---|---|
| LMAT | 100% | -0.85% |
| Pharmaceuticals: Other industry (52 stocks) | 49% Loosely correlated | -0.17% |
| Pharmaceuticals industry (157 stocks) | 30% Poorly correlated | -0.65% |